title: The safety of daclatasvir for the treatment of hepatitis C.
abstract: BACKGROUND
  The direct acting antiviral daclatasvir is an NS5A replication inhibitor active against the entire range of hepatitis C virus genotypes. It is a key step in establishing the goal of an all-oral, ribavirin-free, pan-genotypic regimen against hepatitis C.
  
  
  METHODS
  We review current literature including published abstracts and manuscripts. Evidence was obtained through PubMed/Medline search using listed keywords and through review of published abstracts.
  
  
  CONCLUSIONS
  Daclatasvir introduces a degree of pangenotypic potency currently lacking in other NS5A agents. Emerging literature suggests that daclatasvir in combination with other DAAs will represent a promising option in this difficult to treat populations including posttransplant, genotype 3 and HIV patients.
authors.affiliation: a Division of Gastroenterology , Henry Ford Hospital , Detroit , MI 48202 , USA.
authors.forename: Syed-Mohammed
authors.initials: SM
authors.lastname: Jafri
authors.affiliation: a Division of Gastroenterology , Henry Ford Hospital , Detroit , MI 48202 , USA.
authors.forename: Stuart C
authors.initials: SC
authors.lastname: Gordon
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000998:Antiviral Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002219:Carbamates; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011759:Pyrrolidines; D014633:Valine / Q000031:analogs & derivatives; D014779:Virus Replication / Q000187:drug effects
chemical_list: D000998:Antiviral Agents; D002219:Carbamates; D007093:Imidazoles; D011759:Pyrrolidines; D014633:Valine; C549273:daclatasvir
keywords: daclatasvir; direct acting antivirals; hepatitis C; safety